Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies

Abstract Introduction Psoriatic arthritis (PsA) is a chronic inflammatory disease requiring long-term treatment. Bimekizumab, a monoclonal IgG1 antibody that selectively inhibits interleukin (IL)-17F in addition to IL-17A, has demonstrated tolerability and sustained clinical efficacy for up to 1 yea...

詳細記述

書誌詳細

出版年:	Rheumatology and Therapy
主要な著者:	Philip J. Mease, Joseph F. Merola, Yoshiya Tanaka, Laure Gossec, Iain B. McInnes, Christopher T. Ritchlin, Robert B. M. Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs, Rajan Bajracharya, Vishvesh Shende, Jason Coarse, Laura C. Coates
フォーマット:	論文
言語:	英語
出版事項:	Adis, Springer Healthcare 2024-08-01
主題:	Psoriatic arthritis Efficacy Safety Bimekizumab bDMARD-naïve TNFi-‍inadequate responders
オンライン･アクセス:	https://doi.org/10.1007/s40744-024-00708-8